Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

3.67
+0.23006.69%
Post-market: 3.670.00000.00%19:32 EDT
Volume:707.32K
Turnover:2.56M
Market Cap:363.98M
PE:-2.53
High:3.75
Open:3.52
Low:3.44
Close:3.44
Loading ...

ADC Therapeutics Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
24 Feb

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
04 Feb

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

PR Newswire
·
30 Jan

Jefferies Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)

TIPRANKS
·
24 Jan

ADC Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Jan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
03 Jan

Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires Live
·
01 Jan

ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires Live
·
31 Dec 2024

BRIEF-Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma

Reuters
·
31 Dec 2024

ADC Therapeutics completes enrollment in LOTIS-5 trial

TIPRANKS
·
31 Dec 2024

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of Zynlonta® in Combination With Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
31 Dec 2024

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

PR Newswire
·
31 Dec 2024

ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim

Dow Jones
·
12 Dec 2024

ADC Therapeutics falls -8.9%

TIPRANKS
·
11 Dec 2024

BRIEF-ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Bispecific

Reuters
·
11 Dec 2024

ADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trial

TIPRANKS
·
11 Dec 2024

ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Sa - Zynlonta Plus Glofitamab Shows 94% Orr and 72% Cr Rate

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Sa - No Dose-Limiting Toxicities or High-Grade Crs/Icans Observed

THOMSON REUTERS
·
11 Dec 2024

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

PR Newswire
·
11 Dec 2024